ArticleOncology letters2019
Knockdown of cell division cycle-associated protein 4 expression inhibits proliferation of triple negative breast cancer MDA-MB-231 cells
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- CDCA4 Promotes Lipid Metabolism in Triple-Negative Breast Cancer Through Activation of the SESN2/mTOR/SREBP1 Pathway.Cancers · 2026Article
- The Impact and Molecular Mechanisms of Exercise in Cancer Therapy.Current issues in molecular biology · 2025Review
- IGF2BP2-induced circRNF20 facilitates breast cancer cell proliferation via the HuR/CDCA4 axis.The Kaohsiung journal of medical sciences · 2025Article
- CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma.Frontiers in oncology · 2022Article
- Implications of cell division cycle associated 4 on the Wilm's tumor cells viability via AKT/mTOR signaling pathway.Renal failure · 2021Article
- MiR-497-5p down-regulates CDCA4 to restrains lung squamous cell carcinoma progression.Journal of cardiothoracic surgery · 2021Article
- CDCA1/2/3/5/7/8 as novel prognostic biomarkers and CDCA4/6 as potential targets for gastric cancer.Translational cancer research · 2021Article
- Comparison of anadromous and landlocked Atlantic salmon genomes reveals signatures of parallel and relaxed selection across the Northern Hemisphere.Evolutionary applications · 2021Article
- Article
- Microribonucleic Acid-15a-5p Alters Adriamycin Resistance in Breast Cancer Cells by Targeting Cell Division Cycle-Associated Protein 4.Cancer management and research · 2021Article
- Comprehensive Analysis of Aerobic Exercise-Related Genes Identifies CDCA4 That Promotes the Progression of Osteosarcoma.Frontiers in genetics · 2021Article
- Exploring the Role of TRIP-Brs in Human Breast Cancer: An Investigation of Expression, Clinicopathological Significance, and Prognosis.Molecular therapy oncolytics · 2020Article
- The diagnostic and prognostic value of cell division cycle associated gene family in Hepatocellular Carcinoma.Journal of Cancer · 2020Article
- Polymorphism of XRCC3 in Egyptian Breast Cancer Patients.Pharmacogenomics and personalized medicine · 2020Article
- Comprehensive analysis of the expression and prognosis for CDCAs in head and neck squamous cell carcinoma.PloS one · 2020Article
- Analysis of the Expression ofBioMed research international · 2020Review
- Roles of the CDCA gene family in breast carcinoma.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell division cycle-associated protein 4 (CDCA4), also known as SEI-3/hematopoietic progenitor protein, is a target gene of transcription factor E2F and represses E2F-dependent transcriptional activation and cell proliferation. The present study investigated the effects of CDCA4 knockdown on the regulation of triple negative breast cancer (TNBC) cell proliferation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.